Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New skin spray may heal moisture wounds faster in hospitals

NCT ID NCT06178289

Symptom relief Sponsor: University Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special skin protectant spray (3M Cavilon Advanced) can heal partial-thickness wounds caused by moisture (like from incontinence or stoma leaks) faster and with less pain than usual hospital wound care. About 36 adults in hospitals will be randomly assigned to get either the new spray or standard treatment. Researchers will take daily photos to track healing over up to 21 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient or their legally authorized representative signed informed consent. * The patient is expected to be in the study for the full duration of the trial. * The patient has partial thickness wounds caused by moisture (MASD) i.e., * The patient has IAD category 2A or * Peri-wound MASD or * Peri-stomal MASD. Exclusion Criteria: * Patients with a known hypersensitivity or allergy to acrylate or cyanoacrylate. * The patient requires topical treatment due to a fungal, bacterial or viral infection in the study area. * Intertriginous dermatitis (most often a fungal infection is present). * Peri-fistula MASD (would usually require hospitalization). * The patient has any other local dermatological disease or skin condition interfering with this study. * Patients participating in another study with a known or implied effect on skin barrier function. * Patients who are receiving end-of-life care.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritant dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

injury irritant dermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritant dermatitis Stoma site dermatitis Wound of skin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Oudenaarde

    Oudenaarde, Belgium

  • Ghent University Hospital

    Ghent, Belgium

  • Ziekenhuis Aan de Stroom (ZAS)

    Antwerp, 2030, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.